GBA's "2021 Stock Phantasma"

Sounds like a John Kerry SPAC is on the way!

-Rocket Companies announces special dividend of $1.11 per share 16:15 RKT "Our Company's Board of Directors declared a special dividend of $1.11 per share payable on March 23, 2021 to holders of our Class A common stock of record at the close of business on March 9, 2021. During the year, we achieved significant growth and generated capital at a rate where we were able to fully re-invest in our business and have excess funds available to distribute to our shareholders. We will fund the special dividend from cash distributions of approximately $2.2 billion."

stk was up 11% yesterday but options imply an 18% move.... could be 7-10% upside & that dividend if you can buy in a down day before March 9.

Pinduoduo doubled annual agricultural GMV during pandemic lockdowns
Mar. 02, 2021 7:27 AM ETPinduoduo Inc. (PDD)
  • Pinduoduo (NASDAQ:PDD) doubled the value of agricultural orders handled last year, recording more than 270 billion yuan ($42 billion) in agriculture-related GMV last year, up from 136 billion yuan in 2019.
  • Last December, the company said it was on track to hit 250 billion yuan in agriculture GMV.
  • Pinduoduo partially attributes the outperformance to the pandemic-related lockdowns.
  • In August 2020, Pinduoduo launched Duo Duo Grocery, which helps local farmers sell to
  • consumers.
We have been looking for the right Rare Earths play as a shortage of said elements is around the corner--

Morgan Stanley starts MP Materials at Overweight on accelerating adoption of EVs 07:33 MP As previously reported, Morgan Stanley analyst Carlos De Alba initiated coverage of MP Materials with an Overweight rating and $57 price target. The largest U.S.-based miner of rare earths is a play on the accelerating adoption of electric vehicles, said Alba in an initiation note partially titled "If You Like EV, You'll Love MP." MP's key product, neodymium and praseodymium, or NdPr, is used in the majority of permanent magnets in EV motors and a growing number of offshore wind turbines, said De Alba, who expects these applications to cause NdPr oxide demand and prices to increase.

up 9% yesterday @ $46<--------
 


In fact, shares first managed to struggle to clear the $5 level back in the year 2000. This pattern continued in 2012 as well as 2013 as well as the recent attempt in late 2019. With shares now trading at the $4.56 level, we fully expect another assault at that critical $5 level. Time will tell if shares will be able to break through early this year.

The technical chart definitely has ramifications for how we trade and invest. Why? Because the longer a trend has been in place (resistance at $5 for example), the harder it is for shares to develop a totally new trend. The flipside of this is that if Antares can see new ground for the first time in more than two decades, then that $5 level now becomes really strong support.
 
stonedinvestor said:
Morgan Stanley starts MP Materials at Overweight on accelerating adoption of EVs 07:33 MP As previously reported, Morgan Stanley analyst Carlos De Alba initiated coverage of MP Materials with an Overweight rating and $57 price target. The largest U.S.-based miner of rare earths is a play on the accelerating adoption of electric vehicles, said Alba in an initiation note partially titled "If You Like EV, You'll Love MP." MP's key product, neodymium and praseodymium, or NdPr, is used in the majority of permanent magnets in EV motors and a growing number of offshore wind turbines, said De Alba, who expects these applications to cause NdPr oxide demand and prices to increase.

up 9% yesterday @ $46<--------
More...

Volvo just came out and said their product line will be 100% electric by 2030.

World's gonna need lots of magnets Stoney.
 
YUP... Big time.

Antares Pharma reports Q4 EPS 30c, consensus 3c 07:10 ATRS Reports Q4 revenue $44.1M, consensus $40.75M. Robert F. Apple, President and Chief Executive Officer of Antares Pharma, commented, "We are very proud of our accomplishments this past year that contributed to record annual revenue of $150 million. Despite ongoing challenges due to the global COVID-19 pandemic, the diversification of our business with our proprietary and partner revenue continues to bolster our overall growth, profitability, and cash flow. Driven by strong demand for XYOSTED, our proprietary revenue grew to $63 million in 2020. The reach of our commercial sales organization to urologists and endocrinologists has continued to drive the success of XYOSTED as well as support the expansion of our proprietary portfolio with NOCDURNA. We look forward to further expanding our internal pipeline as we advance our endocrinology and urology assets from successful Pre-IND meetings with the FDA last year to IND submissions this year. Our partner business also had another strong year with total revenue of $87 million driven in large part to the significant increases in market share of Teva's generic EpiPen."
 
Gentherm price target raised to $85 from $53 at Roth Capital 07:06 THRM Roth Capital analyst Matt Koranda raised the firm's price target on Gentherm to $85 from $53 and keeps a Buy rating on the shares. Gentherm's Q4 results were strong, with roughly 20pts of excess growth vs. the industry, while also continuing to outperform margin expectations, Koranda tells investors in a research note. The analyst believes the bookings environment looks highly-attractive for Gentherm, and sees a potential ClimateSense commercial booking on the horizon, which would be transformative for the business in the next cycle.
 
--Lumber Liquidators reports Q4 adjusted EPS $1.06, consensus 50c

--Volkswagen upgraded to Add from Sell at AlphaValue

--Stellantis upgraded to Buy from Add at AlphaValue

--Spin Master upgraded to Buy from Hold at Stifel 05:32 SNMSF

--uniQure price target raised to $100 from $85 at Chardan »

What's That In Granny's Shorts?-INO

Piper lowers Inovio target to $7 after 'decidedly negative' update 05:08 INO Piper Sandler analyst Christopher Raymond lowered the firm's price target on Inovio Pharmaceuticals to $7 from $8 and keeps a Neutral rating on the shares. The analyst says the company's Q4 offered a "decidedly negative development update." The VGX-3100s REVEAL 1 study failed to show statistical significance in the intention to treat population, Raymond tells investors in a research note. He thinks intention to treat, especially in a pivotal trial, has to be the primary population FDA will consider. Raymond finds himself "increasingly skeptical" on Inovio shares.
 
You must log in or register to reply here.
Back
Top